Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Suspended 2Unknown 1Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Dermatologic 6Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Hemangioma 8Hemangioma, Capillary 7Melanoma 6Breast Neoplasms 5Carcinoma, Hepatocellular 4Sarcoma 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Multiple Myeloma 3Hypertension, Portal 3Hemangiosarcoma 3Fallopian Tube Neoplasms 3Urinary Bladder Neoplasms 2Sarcoma, Kaposi 2Ovarian Neoplasms 2Hemangioma, Cavernous, Central Nervous System 2Colorectal Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2von Hippel-Lindau Disease 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Ulcer 1Tuberous Sclerosis 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Spinal Cord Neoplasms 1Smoldering Multiple Myeloma 1Skin Neoplasms 1

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236aldesleukin 134Cyclophosphamide 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 67dabrafenib 65fludarabine phosphate 61sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35cobimetinib 32Magnetic Resonance Spectroscopy 32Introns 30Specimen Handling 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Melanoma × Propranolol × Clear all
NCT05968690 2025-09-18

Naltrexone and Propranolol Combined With Immunotherapy

Rutgers, The State University of New Jersey

Phase 1 Recruiting
12 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT03384836 2025-07-02

Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery

Roswell Park Cancer Institute

Phase 1/2 Suspended
47 enrolled
Dermatologic

Melanoma

NCT02013492 2022-12-06

Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery

Ohio State University Comprehensive Cancer Center

Phase EARLY_PHASE1 Completed
1 enrolled
BreastDermatologicGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Hepatocellular, Melanoma, Breast Neoplasms, Male

NCT01988831 2019-05-10

Efficacy of Propranolol Treatment to Prevent Melanoma Progression

University Hospital, Geneva

Phase 2 Suspended
450 enrolled
Dermatologic

Melanoma, Recurrence

NCT01705392 2017-02-24

Bevacizumab vs Dacarbazine in Metastatic Melanoma

Haukeland University Hospital

Phase 2 Terminated
2 enrolled
Dermatologic

Melanoma

NCT02962947 2016-11-15

MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients

Azienda Sanitaria di Firenze

Phase 2/3 Unknown
546 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡